Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › FDA Approves Expanded Use of Agilent CDx for Keytruda in Head and Neck Cancer

FDA Approves Expanded Use of Agilent CDx for Keytruda in Head and Neck Cancer

Jun 11, 2019
|
staff reporter

NEW YORK (360Dx) – Agilent Technologies announced on Tuesday that the US Food and Drug Administration has expanded its approval of the firm's Dako PD-L1 IHC 22C3 pharmDx assay as a companion diagnostic test for Merck's anti-PDL-1 immunotherapy pembrolizumab (Keytruda) for head and neck squamous cell carcinoma (HNSCC).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Regulatory News & FDA Approvals

  1. FDA Grants EUA for UCSF, Broad Institute, BioSewoom Coronavirus Tests

  2. FDA Letter Warns About False-Positive Results From Becton Dickinson SARS-CoV-2 Test

  3. Vela Diagnostics Automated Coronavirus Test Gets CE-IVD Mark

  4. Diazyme Receives Emergency Use Authorization for Coronavirus Antibody Test

  5. BD Rapid Coronavirus Antigen Test Gets FDA Emergency Use Authorization

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.